-
Trolox for Redox-Controlled Organoid Assays
2026-09-04
Trolox adds a practical redox-control layer to pancreatic ductal organoid workflows, antioxidant assays, and oxidative injury research. This guide shows how to formulate, dose, benchmark, and troubleshoot Trolox without confusing cytoprotection with altered organoid growth or assay artifacts.
-
Brefeldin A Workflows for ER Stress Studies
2026-09-04
Brefeldin A converts a defined ER-to-Golgi trafficking block into a practical system for studying secretion, ER quality control, and cancer-cell phenotypes. This guide connects concentration and time-course design with apoptosis, migration, and UBR1/UBR2-centered ER stress assays.
-
From hly Biology to Better qPCR Translation
2026-09-03
A translational guide to using mechanistic gene-expression data from Listeria monocytogenes biofilm research to design faster, more reproducible, and better-controlled qPCR workflows.
-
Docking Vitamins Against SARS-CoV-2 Targets
2026-09-03
The reference study used virtual screening, molecular docking, and molecular dynamics simulations to evaluate repurposed vitamins against the SARS-CoV-2 spike receptor-binding domain and 3CL protease. Its main contribution is a dual-target computational framework that links predicted inhibition of viral entry with interference in viral polyprotein processing, while also highlighting the need for biochemical and cellular validation.
-
Drug-Sensitized Yeast for mTOR Inhibitor Discovery
2026-09-02
The 2025 GeroScience study develops a genetically drug-sensitized Saccharomyces cerevisiae platform that substantially improves growth-based detection of TOR inhibitors. Its results validate the system with known compounds, identify aminophylline as a TOR1-dependent growth inhibitor, and show no evidence that Canagliflozin inhibits TOR in this yeast model.
-
Antiarrhythmic Drugs and KCa2 Channels in AF
2026-09-02
The reference study systematically tested clinically used antiarrhythmic drugs against human KCa2.2 and KCa2.3 channels using automated whole-cell patch clamp. Only dofetilide and propafenone inhibited these channels, while Dronedarone and the other tested agents showed no inhibition at concentrations likely to explain their clinical antiarrhythmic effects.
-
Acetoacetic Acid Sodium Salt: Assay Logic
2026-09-01
Acetoacetic acid sodium salt is a versatile model for ketone-body and energy metabolism research. This guide connects its chemical handling to assay interpretation and extracts a practical internal-standard lesson from isotope-labeled synthesis research.
-
Vancomycin Hydrochloride Assay Workflows
2026-09-01
Build reproducible Gram-positive susceptibility, resistance, and infection-model workflows around a mechanism-defined glycopeptide antibacterial agent. This guide connects solvent handling and plate-based testing with translational Clostridium difficile research while clearly separating validated evidence from practical assay recommendations.
-
CAY10499: Inhibitor of Human Hormone Sensitive Lipase
2026-08-31
CAY10499 enables controlled interrogation of HSL, MGL, FAAH, and endocannabinoid-linked lipid flux in biochemical and cellular models. Its value is especially clear in EV-driven tumor-macrophage studies, where it can help separate lipid hydrolysis from ACLY-dependent lipid synthesis without being mistaken for a direct ACLY inhibitor.
-
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-08-31
Masitinib (AB1010), SKU A2942, provides a DMSO-compatible research tool for examining KIT and PDGFRα/β signaling in biochemical, cellular, mast-cell, and cancer models. It is not suitable for aqueous or ethanol-based protocols, broad-spectrum kinase screening, clinical dosing decisions, or conclusions requiring paper-specific validation.
-
RHEB Neddylation Activates mTORC1 in Liver Cancer
2026-08-30
The reference study identifies RHEB as a non-cullin substrate of the UBE2F–SAG neddylation system and shows that modification at K169 strengthens RHEB lysosomal localization and GTP binding. This mechanism links elevated UBE2F activity to mTORC1 signaling, liver steatosis, hepatocellular tumorigenesis, and patient outcome, while suggesting experimental strategies for validating related protein-modification pathways.
-
Veratridine: A Mechanistic Assay Framework
2026-08-29
Veratridine is a voltage-gated sodium channel opener that can turn membrane depolarization into a carefully interpretable model of excitotoxic injury. This article connects channel pharmacology, assay design, and evidence-based readout selection rather than treating neurotoxicity as a single endpoint.
-
Temafloxacin Pharmacokinetics: Evidence and Implications
2026-08-28
Dudley’s review integrates human pharmacokinetic studies of temafloxacin, identified in the publication title as temafloxadn, to explain its high oral bioavailability, prolonged half-life, renal elimination, and dosing implications. The analysis provides a useful framework for interpreting antimicrobial exposure, while its findings should not be transferred directly to Sulfamonomethoxine or other veterinary agents without compound-specific data.
-
Dual-Pathway Nanotherapy for Gefitinib Resistance
2026-08-28
Deng and colleagues describe a rational gefitinib–crizotinib combination that simultaneously suppresses PI3K–AKT signaling and compensatory ERK activation in gefitinib-resistant lung adenocarcinoma models. The study further integrates dual-drug polyphosphoester nanoparticles with cell, xenograft, and zebrafish validation, providing a mechanistic framework for treating resistance and metastatic spread.
-
Acetylcholine Chloride in Gut–Brain Translation
2026-08-27
A translational framework for using Acetylcholine Chloride as a defined cholinergic comparator in gut–vagus–brain studies, informed by recent findings linking Bacteroides fragilis, vagal signaling, and seizure suppression.